North Fourth Asset Management, LP 89bio, Inc. Transaction History
North Fourth Asset Management, LP
- $163 Million
- Q3 2023
A detailed history of North Fourth Asset Management, LP transactions in 89bio, Inc. stock. As of the latest transaction made, North Fourth Asset Management, LP holds 100,000 shares of ETNB stock, worth $808,000. This represents 0.33% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$808,000% of portfolio
0.33%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ETNB
# of Institutions
172Shares Held
124MCall Options Held
78.7KPut Options Held
979K-
Janus Henderson Group PLC London, X016.5MShares$133 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$115 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$82.4 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$60.4 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$56.7 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $376M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...